This clinical trial is focused on studying the effects of a medication called landiolol hydrochloride in patients undergoing surgery for the mitral valve, which is a valve in the heart. The trial aims to see if this medication can help reduce the chances of developing a condition known as Low-Cardiac Output Syndrome (LCOS) after surgery. LCOS is a situation where the heart does not pump enough blood to meet the body’s needs, which can happen after heart surgery.

In this study, participants will receive either the medication Landiobloc, which contains landiolol hydrochloride, or a placebo. Landiolol hydrochloride is a type of medication known as a beta-blocker, which helps to slow down the heart rate and reduce the heart’s workload. The study will also use a solution called sodium chloride, commonly known as saline, which is often used in medical settings to provide fluids and electrolytes.

The purpose of the study is to determine if landiolol hydrochloride can effectively reduce the occurrence of LCOS after mitral valve surgery. Participants will be randomly assigned to receive either the medication or a placebo during their surgery. The study will monitor the participants’ heart function and recovery after surgery to assess the effects of the treatment. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results.